Prot #IMC-F106C-301: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Project: Research project

Project Details

StatusActive
Effective start/end date9/30/24 → 9/30/27

Funding

  • Worldwide Clinical Trials, Inc. (Prot #IMC-F106C-301 // Prot #IMC-F106C-301)
  • Immunocore Limited (Prot #IMC-F106C-301 // Prot #IMC-F106C-301)